New insights into the mechanism of low high-density lipoprotein cholesterol in obesity
Open accessThe DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Abstract
Obesity, a significant risk factor for various chronic diseases, is universally related to dyslipidemia mainly represented by decreasing high-density lipoprotein cholesterol (HDL-C), which plays an indispensible role in development of cardiovascular disease (CVD). However, the mechanisms underlying obesity and low HDL-C have not been fully elucidated. Previous studies have focused on the alteration of HDL catabolism in circulation following elevated triglyceride (TG). But recent findings suggested that liver and fat tissue played pivotal role in obesity related low HDL-C. Some new molecular pathways like microRNA have also been proposed in the regulation of HDL metabolism in obesity. This article will review recent advances in understanding of the potential mechanism of low HDL-C in obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The concentrations of plasma apolipoprotein (apo) B are also often increased, partly due to the hepatic overproduction of apo B containing lipoproteins [6,7].”
From Dyslipidemia in obesity: Mechanisms and potential targets (2013) · cites this paper as [7]
In the citing paper
“The typical dyslipidemia of obesity consists of increased triglycerides (TG) and FFA, decreased HDL-C with HDL dysfunction and normal or slightly increased LDL-C with increased small dense LDL.”
From Dyslipidemia in obesity: Mechanisms and potential targets (2013) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ford, E. S., Giles, W. H., & Dietz, W. H. (2002) · JAMA · doi:10.1001/jama.287.3.356 · Cited by 6,698
Paradoxical Decrease of an Adipose-Specific Protein, Adiponectin, in Obesity
Arita, Y., Kihara, S., Ouchi, N., Takahashi, M., Maeda, K., Miyagawa, J.-I., Hotta, K., Shimomura, I., Nakamura, T., Miyaoka, K., et al. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0255 · Cited by 4,856
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
Haslam, D. W., & James, W. P. T. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67483-1 · Cited by 3,757
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Poirier, P., Giles, T. D., Bray, G. A., Hong, Y., Stern, J. S., Pi-Sunyer, F. X., & Eckel, R. H. (2006) · Circulation · doi:10.1161/circulationaha.106.171016 · Cited by 3,165
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1001689 · Cited by 1,943 · cited 1×
“Considering cholesterol efflux capacity, independently of the HDL-C level, is the main metric of HDL function and has a strong inverse association with coronary artery disease [26], the impaired cholesterol efflux capacity may have a more crucial impact on the development of CVD in obese individuals.”
BackgroundInsulin resistance and cardiovascular disease
Ginsberg, H. N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10762 · Cited by 1,358
Ouchi, N., Kihara, S., Arita, Y., Nishida, M., Matsuyama, A., Okamoto, Y., Ishigami, M., Kuriyama, H., Kishida, K., Nishizawa, H., et al. (2001) · Circulation · doi:10.1161/01.cir.103.8.1057 · Cited by 1,277
MiR-33 Contributes to the Regulation of Cholesterol Homeostasis
Rayner, K. J., Suárez, Y., Dávalos, A., Parathath, S., Fitzgerald, M. L., Tamehiro, N., Fisher, E. A., Moore, K. J., & Fernández-Hernando, C. (2010) · Science · doi:10.1126/science.1189862 · Cited by 1,260
The Emerging Risk Factors Collaboration (2011) · The Lancet · doi:10.1016/s0140-6736(11)60105-0 · Cited by 1,216
MicroRNA-33 and the SREBP Host Genes Cooperate to Control Cholesterol Homeostasis
Najafi-Shoushtari, S. H., Kristo, F., Li, Y., Shioda, T., Cohen, D. E., Gerszten, R. E., & Näär, A. M. (2010) · Science · doi:10.1126/science.1189123 · Cited by 957
Inazu, A., Brown, M. L., Hesler, C. B., Agellon, L. B., Koizumi, J., Takata, K., Maruhama, Y., Mabuchi, H., & Tall, A. R. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011013231803 · Cited by 861
Van Lenten, B. J., Hama, S. Y., de Beer, F. C., Stafforini, D. M., McIntyre, T. M., Prescott, S. M., La Du, B. N., Fogelman, A. M., & Navab, M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118345 · Cited by 840
The Framingham Offspring Study
Allhoff, P., Laaser, U., & Heinrich, J. (1991) · Kompendium der Lipid-Studien · doi:10.1007/978-3-642-95642-3_25 · Cited by 831
Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol
Brousseau, M. E., Schaefer, E. J., Wolfe, M. L., Bloedon, L. T., Digenio, A. G., Clark, R. W., Mancuso, J. P., & Rader, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031766 · Cited by 774 · cited 1×
“Hence, inhibition of CETP with CETP inhibitors, such as torcetrapib, was believed to be beneficial for HDL-C metabolism and finally prevent cardiovascular events [41].”
BackgroundAdiponectin as a Biomarker of the Metabolic Syndrome
Ryo, M., Nakamura, T., Kihara, S., Kumada, M., Shibazaki, S., Takahashi, M., Nagai, M., Matsuzawa, Y., & Funahashi, T. (2004) · Circulation Journal · doi:10.1253/circj.68.975 · Cited by 767
Safety of anacetrapib in patients with or at high risk for coronary heart disease
Cannon, C. P., Shah, S., Dansky, H. M., Davidson, M., Brinton, E. A., Gotto, A. M., Stepanavage, M., Liu, S. X., Gibbons, P., Ashraf, T. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1009744 · Cited by 749 · cited 1×
“Recent clinical trial has demonstrated that anacetrapib (another CETP inhibitor) had robust impact on LDL and HDL cholesterol and did not result in the adverse effects observed with torcetrapib [43].”
BackgroundTreatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2
Furuhashi, M., Tuncman, G., Görgün, C. Z., Makowski, L., Atsumi, G., Vaillancourt, E., Kono, K., Babaev, V. R., Fazio, S., Linton, M. F., et al. (2007) · Nature · doi:10.1038/nature05844 · Cited by 718
Overproduction of large VLDL particles is driven by increased liver fat content in man
Adiels, M., Taskinen, M.-R., Packard, C., Caslake, M. J., Soro-Paavonen, A., Westerbacka, J., Vehkavaara, S., Häkkinen, A., Olofsson, S.-O., Yki-Järvinen, H., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0125-z · Cited by 690
Rayner, K. J., Sheedy, F. J., Esau, C. C., Hussain, F. N., Temel, R. E., Parathath, S., van Gils, J. M., Rayner, A. J., Chang, A. N., Suarez, Y., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57275 · Cited by 690 · cited 2×
“Rayner et al [87] studied the impact of miR-33 inhibition in mice deficient for LDL receptor (Ldlr mice), with established atherosclerotic plaques.”
BackgroundFabbrini, E., Mohammed, B. S., Magkos, F., Korenblat, K. M., Patterson, B. W., & Klein, S. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.11.038 · Cited by 631
The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance
Goossens, G. H. (2008) · Physiology & Behavior · doi:10.1016/j.physbeh.2007.10.010 · Cited by 591
Gotto, A. M., Whitney, E., Stein, E. A., Shapiro, D. R., Clearfield, M., Weis, S., Jou, J. Y., Langendörfer, A., Beere, P. A., Watson, D. J., et al. (2000) · Circulation · doi:10.1161/01.cir.101.5.477 · Cited by 563
Chen, G., Liang, G., Ou, J., Goldstein, J. L., & Brown, M. S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404297101 · Cited by 551
HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis
Tall, A. R., Yvan-Charvet, L., Terasaka, N., Pagler, T., & Wang, N. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.03.001 · Cited by 540 · cited 2×
“Unfortunately, the large clinical trial ILLUMINATE was stopped prematurely as a result of an excess of deaths and morbidity in the group receiving torcetrapib and atorvastatin compared to atorvastatin alone [42].”
BackgroundIntestinal ABCA1 directly contributes to HDL biogenesis in vivo
Brunham, L. R. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27352 · Cited by 519 · cited 1×
“Although extrahepatic ABCA1 is essential for the maturation of HDL particles, it contributes little to the plasma HDL-C levels [82,83].”
BackgroundYAMAMOTO, Y., HIROSE, H., SAITO, I., TOMITA, M., TANIYAMA, M., MATSUBARA, K., OKAZAKI, Y., ISHII, T., NISHIKAI, K., & SARUTA, T. (2002) · Clinical Science · doi:10.1042/cs1030137 · Cited by 490
High-Density Lipoprotein as a Therapeutic Target: A Systematic Review
Singh, I. M., Shishehbor, M. H., & Ansell, B. J. (2007) · JAMA · doi:10.1001/jama.298.7.786 · Cited by 468 · cited 1×
“It is widely known that low plasma HDL-C levels are inversely related to the risk of CVD and independent of other risk factors [4,5].”
BackgroundTimmins, J. M., Lee, J.-Y., Boudyguina, E., Kluckman, K. D., Brunham, L. R., Mulya, A., Gebre, A. K., Coutinho, J. M., Colvin, P. L., Smith, T. L., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23915 · Cited by 447 · cited 1×
“the other hand, 80% decrease in plasma HDL-C was observed in mice with liver-specific deletion of ABCA1 [80].”
BackgroundSorrentino, S. A., Besler, C., Rohrer, L., Meyer, M., Heinrich, K., Bahlmann, F. H., Mueller, M., Horváth, T., Doerries, C., Heinemann, M., et al. (2010) · Circulation · doi:10.1161/circulationaha.108.836346 · Cited by 402
Inflammation Impairs Reverse Cholesterol Transport In Vivo
McGillicuddy, F. C., de la Llera Moya, M., Hinkle, C. C., Joshi, M. R., Chiquoine, E. H., Billheimer, J. T., Rothblat, G. H., & Reilly, M. P. (2009) · Circulation · doi:10.1161/circulationaha.108.810721 · Cited by 391
Horie, T., Ono, K., Horiguchi, M., Nishi, H., Nakamura, T., Nagao, K., Kinoshita, M., Kuwabara, Y., Marusawa, H., Iwanaga, Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008499107 · Cited by 384
Expression of miR-33 from an SREBP2 Intron Inhibits Cholesterol Export and Fatty Acid Oxidation*
Gerin, I., Clerbaux, L.-A., Haumont, O., Lanthier, N., Das, A. K., Burant, C. F., Leclercq, I. A., MacDougald, O. A., & Bommer, G. T. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.152090 · Cited by 382 · cited 1×
“subunit of the mitochondrial trifunctional protein) [88].”
Lamon-Fava, S., Wilson, P. W. F., & Schaefer, E. J. (1996) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.16.12.1509 · Cited by 327
Multiple Risk Factors for Cardiovascular Disease and Diabetes Mellitus
Smith, S. C. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.01.002 · Cited by 325
Fernández-Hernando, C., Suárez, Y., Rayner, K. J., & Moore, K. J. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283428d9d · Cited by 308
Shah, P. K., Kaul, S., Nilsson, J., & Cercek, B. (2001) · Circulation · doi:10.1161/hc4501.098468 · Cited by 295
Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism
Shachter, N. S. (2001) · Current Opinion in Lipidology · doi:10.1097/00041433-200106000-00009 · Cited by 288 · cited 1×
“By inhibiting lipoprotein lipase and hepatic uptake, apoC-III can impair the hydrolysis of TG [45].”
BackgroundAttie, A. D., Kastelein, J. P., & Hayden, M. R. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)31498-x · Cited by 284
Nieves, D. J., Cnop, M., Retzlaff, B., Walden, C. E., Brunzell, J. D., Knopp, R. H., & Kahn, S. E. (2003) · Diabetes · doi:10.2337/diabetes.52.1.172 · Cited by 281 · cited 1×
“Increasing intra-abdominal fat area, quantified by computed tomography scan, was an important determinant of decreased HDL-C [21].”
BackgroundA review of CETP and its relation to atherosclerosis
de Grooth, G. J., Klerkx, A. H. E. M., Stroes, E. S. G., Stalenhoef, A. F. H., Kastelein, J. J. P., & Kuivenhoven, J. A. (2004) · Journal of Lipid Research · doi:10.1194/jlr.r400007-jlr200 · Cited by 269
Ji, Y., Wang, N., Ramakrishnan, R., Sehayek, E., Huszar, D., Breslow, J. L., & Tall, A. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.47.33398 · Cited by 263
Monocyte/macrophage expression of ABCA1 has minimal contribution to plasma HDL levels
Haghpassand, M., Bourassa, P.-A. K., Francone, O. L., & Aiello, R. J. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12810 · Cited by 256
Després, J. P., Moorjani, S., Ferland, M., Tremblay, A., Lupien, P. J., Nadeau, A., Pinault, S., Thériault, G., & Bouchard, C. (1989) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.9.2.203 · Cited by 255
The Lipid Research Clinics Program Prevalence Study
Allhoff, P., Laaser, U., & Heinrich, J. (1991) · Kompendium der Lipid-Studien · doi:10.1007/978-3-642-95642-3_39 · Cited by 253
Lipid profiles in untreated patients with rheumatoid arthritis.
Park, Y., Lee, S. K., Lee, W. K., Suh, C., Lee, C. W., Lee, C. H., Song, C. H., & Lee, J. (1999) · PubMed · Cited by 252
Baratta, R., Amato, S., Degano, C., Farina, M. G., Patanè, G., Vigneri, R., & Frittitta, L. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031777 · Cited by 252
Pettinelli, P., del Pozo, T., Araya, J., Rodrigo, R., Araya, A. V., Smok, G., Csendes, A., Gutierrez, L., Rojas, J., Korn, O., et al. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.08.015 · Cited by 229
Endo, M., Masaki, T., Seike, M., & Yoshimatsu, H. (2007) · PubMed · Cited by 225
Shah, P. K., Kaul, S., Nilsson, J., & Cercek, B. (2001) · Circulation · doi:10.1161/hc4401.098467 · Cited by 222
Effect of Obesity on High‐density Lipoprotein Metabolism
Rashid, S., & Genest, J. (2007) · Obesity · doi:10.1038/oby.2007.342 · Cited by 212
Adipose tissue and cholesterol metabolism.
Krause, B. R., & Hartman, A. D. (1984) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37830-5 · Cited by 210
DULLAART, R. P. F., SLUITER, W. J., DIKKESCHEI, L. D., HOOGENBERG, K., & TOL, A. V. (1994) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1994.tb00987.x · Cited by 195
Adiponectin suppresses hepatic SREBP1c expression in an AdipoR1/LKB1/AMPK dependent pathway
Awazawa, M., Ueki, K., Inabe, K., Yamauchi, T., Kaneko, K., Okazaki, Y., Bardeesy, N., Ohnishi, S., Nagai, R., & Kadowaki, T. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.02.131 · Cited by 186
YAMAMOTO, Y., Hirose, H., Saito, I., et al. (2002) · Clinical Science · doi:10.1042/cs20010336 · Cited by 182
Badellino, K. O., Wolfe, M. L., Reilly, M. P., & Rader, D. J. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0030022 · Cited by 173
Dysfunctional HDL as a Diagnostic and Therapeutic Target
Smith, J. D. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.179226 · Cited by 170
Increasing HDL Cholesterol Levels
Brewer, H. B. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048023 · Cited by 166
Matsuura, F., Oku, H., Koseki, M., Sandoval, J. C., Yuasa‐Kawase, M., Tsubakio‐Yamamoto, K., Masuda, D., Maeda, N., Tsujii, K., Ishigami, M., et al. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.05.040 · Cited by 163
Hayek, T., Ito, Y., Azrolan, N., Verdery, R. B., Aalto-Setälä, K., Walsh, A., & Breslow, J. L. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116375 · Cited by 149
CAGEN, L. M., DENG, X., WILCOX, H. G., PARK, E. A., RAGHOW, R., & ELAM, M. B. (2005) · Biochemical Journal · doi:10.1042/bj20040162 · Cited by 142
Khovidhunkit, W., Moser, A. H., Shigenaga, J. K., Grunfeld, C., & Feingold, K. R. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m300100-jlr200 · Cited by 142
Adiponectin Is an Important Determinant of ApoA-I Catabolism
Vergès, B., Petit, J. M., Duvillard, L., Dautin, G., Florentin, E., Galland, F., & Gambert, P. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000219611.50066.bd · Cited by 141
Obesity‐related Changes in High‐density Lipoprotein Metabolism
Mooradian, A. D., Haas, M. J., Wehmeier, K. R., & Wong, N. C. W. (2008) · Obesity · doi:10.1038/oby.2008.202 · Cited by 139
Hugh Sinclair Lecture: The regulation and remodelling of HDL by plasma factors
Barter, P. J. (2002) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(02)00041-7 · Cited by 138
Adipocyte Modulation of High-Density Lipoprotein Cholesterol
Zhang, Y., McGillicuddy, F. C., Hinkle, C. C., O'Neill, S., Glick, J. M., Rothblat, G. H., & Reilly, M. P. (2010) · Circulation · doi:10.1161/circulationaha.109.897330 · Cited by 135
Glueck, C. J., Hl, T., Jacobs, D. R., Morrison, J. A., Beaglehole, R., & Williams, O. D. (1980) · PubMed · Cited by 132
Influence of weight reduction on plasma lipoproteins in obese patients.
Wolf, R. N., & Grundy, S. M. (1983) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.3.2.160 · Cited by 130
Human adipocyte cholesterol. Concentration, localization, synthesis, and turnover.
Schreibman, P. H., & Dell, R. B. (1975) · Journal of Clinical Investigation · doi:10.1172/jci108028 · Cited by 124
Carr, M. C., Hokanson, J. E., Zambon, A., Deeb, S. S., Barrett, P. H. R., Purnell, J. Q., & Brunzell, J. D. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.6.7586 · Cited by 119
The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states
Rashid, S., Uffelman, K. D., & Lewis, G. F. (2002) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(01)00191-x · Cited by 113
Molecular regulation of macrophage reverse cholesterol transport
Wang, X., & Rader, D. J. (2007) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3281ec5113 · Cited by 113
Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes
Cabré, A., Lázaro, I., Girona, J., Manzanares, J. M., Marimón, F., Plana, N., Heras, M., & Masana, L. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800102-jlr200 · Cited by 106
Alterations of plasma lipids in mice via adenoviral-mediated hepatic overexpression of human ABCA1
Wellington, C. L., Brunham, L. R., Zhou, S., Singaraja, R. R., Visscher, H., Gelfer, A., Ross, C., James, E., Liu, G., Huber, M. T., et al. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m300110-jlr200 · Cited by 100
Adipocyte cholesterol balance in obesity
Lay, S. L., Ferré, P., & Dugail, I. (2004) · Biochemical Society Transactions · doi:10.1042/bst0320103 · Cited by 97
Adiponectin deficiency suppresses ABCA1 expression and ApoA‐I synthesis in the liver
Oku, H., Matsuura, F., Koseki, M., Sandoval, J. C., Yuasa-Kawase, M., Tsubakio-Yamamoto, K., Masuda, D., Maeda, N., Ohama, T., Ishigami, M., et al. (2007) · FEBS Letters · doi:10.1016/j.febslet.2007.09.038 · Cited by 93
Singaraja, R. R., Van Eck, M., Bissada, N., Zimetti, F., Collins, H. L., Hildebrand, R. B., Hayden, A., Brunham, L. R., Kang, M. H., Fruchart, J.-C., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.621433 · Cited by 84
Suppression of apolipoprotein AI gene expression in HepG2 cells by TNF α and IL-1β
Haas, M. J., Horani, M., Mreyoud, A., Plummer, B., Wong, N. C. W., & Mooradian, A. D. (2003) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2003.08.004 · Cited by 70
Characterization of high density lipoprotein binding to human adipocyte plasma membranes.
Fong, B. S., Rodrigues, P. O., Salter, A. M., Yip, B. P., Despres, J. P., Angel, A., & Gregg, R. E. (1985) · Journal of Clinical Investigation · doi:10.1172/jci111893 · Cited by 70
Dobiášová, M., & Frohlich, J. (1998) · PubMed · Cited by 70
On the hepatic mechanism of HDL assembly by the ABCA1/apoA-I pathway
Tsujita, M., Wu, C.-A., Abe-Dohmae, S., Usui, S., Okazaki, M., & Yokoyama, S. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m400402-jlr200 · Cited by 67
Yvan‐Charvet, L., Bobard, A., Bossard, P., Massiéra, F., Rousset, X., Ailhaud, G. P., Teboul, M., Ferré, P., Dagher, G., & Quignard‐Boulangé, A. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.106.136382 · Cited by 67
Brewer, H. B., & Santamarina-Fojo, S. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00769-0 · Cited by 63
High molecular weight adiponectin reduces apolipoprotein B and E release in human hepatocytes
Neumeier, M., Sigrüener, A., Eggenhofer, E., Weigert, J., Weiß, T. S., Schaeffler, A., Schlitt, H. J., Aslanidis, C., Piso, P., Langmann, T., et al. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.11.058 · Cited by 62
Chan, D. C., Nguyen, M. N., Watts, G. F., & Barrett, P. H. R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2676 · Cited by 62
Myeloperoxidase, inflammation, and dysfunctional high-density lipoprotein
Smith, J. D. (2010) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2010.08.007 · Cited by 62
Increased hepatic VLDL secretion, lipogenesis, and SREBP-1 expression in the corpulent JCR:LA-cp rat
Elam, M. B., Wilcox, H. G., Cagen, L. M., Deng, X., Raghow, R., Kumar, P., Heimberg, M., & Russell, J. C. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)31533-9 · Cited by 62
Gidding, S. S., Stone, N. J., Bookstein, L. C., Laskarzewski, P. M., & Stein, E. A. (1998) · The Journal of Pediatrics · doi:10.1016/s0022-3476(98)70227-6 · Cited by 54
Stimulation of lipolysis enhances the rate of cholesterol efflux to HDL in adipocytes
Verghese, P. B., Arrese, E. L., & Soulages, J. L. (2007) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-007-9447-0 · Cited by 51
Altered properties of high density lipoprotein subfractions in obese subjects
Sasahara, T., Yamashita, T., Sviridov, D., Fidge, N., & Nestel, P. (1997) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37268-0 · Cited by 50
Sasahara, T., Nestel, P., Fidge, N., & Sviridov, D. (1998) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33293-4 · Cited by 50
Beers, A., Haas, M. J., Wong, N. C. W., & Mooradian, A. D. (2006) · Biochemistry · doi:10.1021/bi0518040 · Cited by 47
Carr, M. C. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.6.2831 · Cited by 47
Biochemical and Physical Properties of Remnant-HDL2 and of Preβ1-HDL Produced by Hepatic Lipase
Guendouzi, K., Jaspard‐Vinassa, B., Barbaras, R., Motta, C., Vieu, C., Marcel, Y. L., Chap, H., Perret, B., & Collet, X. (1999) · Biochemistry · doi:10.1021/bi9815086 · Cited by 41
Vassiliou, G., & McPherson, R. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000134295.09932.60 · Cited by 37
Xiao, C., Watanabe, T., Zhang, Y., Trigatti, B. L., Szeto, L., Connelly, P. W., Marcovina, S. M., Vaisar, T., Heinecke, J. W., & Lewis, G. F. (2008) · Circulation Research · doi:10.1161/circresaha.108.178756 · Cited by 36
Williams, P. T. (2004) · Metabolism · doi:10.1016/j.metabol.2004.01.004 · Cited by 31
Elam, M. B., Yellaturu, C. R., Howell, G., Deng, X., Cowan, G. S. M., Kumar, P., Park, E. A., Hiler, M. L., Wilcox, H. G., Hughes, T. A., et al. (2009) · Metabolism · doi:10.1016/j.metabol.2009.09.001 · Cited by 31
Rashid, S., Patterson, B. W., & Lewis, G. F. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r600008-jlr200 · Cited by 31
Unique Pathway for Cholesterol Uptake in Fat Cells
Fazio, S., & Linton, M. F. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000140821.25572.1b · Cited by 15
Brown, R., & Rader, D. J. (2008) · Circulation Research · doi:10.1161/circresaha.108.180638 · Cited by 10
Navarro, E., Mijac, V., Flórez, H., & Ryder, E. (2025) · Archivos Latinoamericanos de Nutrición · doi:10.37527/2010.60.2.008 · Cited by 5
Cited by
Dyslipidemia in obesity: Mechanisms and potential targets
Klop, B., Elte, J., & Cabezas, M. (2013) · Nutrients · doi:10.3390/nu5041218 · Cited by 1,665
“The concentrations of plasma apolipoprotein (apo) B are also often increased, partly due to the hepatic overproduction of apo B containing lipoproteins [6,7].”
BackgroundDIANA miRPath v.2.0: investigating the combinatorial effect of microRNAs in pathways
Vlachos, I. S., Kostoulas, N., Vergoulis, T., Georgakilas, G., Reczko, M., Maragkakis, M., Paraskevopoulou, M. D., Prionidis, K., Dalamagas, T., & Hatzigeorgiou, A. G. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks494 · Cited by 526
Thijssen, E., van Caam, A., & van der Kraan, P. M. (2015) · Rheumatology · doi:10.1093/rheumatology/keu464 · Cited by 362
Fat Depots, Free Fatty Acids, and Dyslipidemia
Ebbert, J., & Jensen, M. (2013) · Nutrients · doi:10.3390/nu5020498 · Cited by 349
Obesity-Related Changes in High-Density Lipoprotein Metabolism and Function
Stadler, J. T., & Marsche, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238985 · Cited by 200
Metadata
- Authors
- Wang, H., & Peng, D.-Q.
- Affiliations
- Central South University (CN)
- ORCID
- Wang, Hao
- Venue
- Lipids in Health and Disease
- Published
- 2011
- Volume
- 10
- Issue
- 1
- Pages
- 176
- ISSN
- 1476-511X (ISSN-L)
- PMC
- PMC3207906
- OpenAlex
- W2171444347
- Cited by
- 140
- References
- 103
- Citations by year
- 2026: 4 · 2025: 15 · 2024: 4 · 2023: 11 · 2022: 10 · 2021: 12 · 2020: 18 · 2019: 12 · 2018: 7 · 2017: 3 · 2016: 9 · 2015: 8 · 2014: 6 · 2013: 17 · 2012: 4
- FWCI
- 1.56
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Lipids in Health and Disease (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Natural Science Foundation of China (81170260)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- low HDL cholesterol, obesity, dyslipidemia, HDL metabolism, HDL catabolism, triglycerides, liver, adipose tissue, microRNA, cardiovascular disease
- MeSH terms
- Animals, Cardiovascular Diseases, Cholesterol, Humans, Lipoproteins, HDL, Cholesterol, LDL, Obesity, Adipocytes, ATP-Binding Cassette Transporters, Hepatocytes, MicroRNAs, Dyslipidemias, Sterol Regulatory Element Binding Protein 1, ATP Binding Cassette Transporter 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.